[go: up one dir, main page]

PE20070078A1 - Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa - Google Patents

Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa

Info

Publication number
PE20070078A1
PE20070078A1 PE2006000654A PE2006000654A PE20070078A1 PE 20070078 A1 PE20070078 A1 PE 20070078A1 PE 2006000654 A PE2006000654 A PE 2006000654A PE 2006000654 A PE2006000654 A PE 2006000654A PE 20070078 A1 PE20070078 A1 PE 20070078A1
Authority
PE
Peru
Prior art keywords
aspartile
macrociclic
protease inhibitors
heterocyclic compounds
alkenyl
Prior art date
Application number
PE2006000654A
Other languages
English (en)
Inventor
Ulrich Iserloh
Zhaoning Zhu
Andrew Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20070078A1 publication Critical patent/PE20070078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE W ES UN ENLACE, -C(=S)(C(R3)(R4))a-, -(C(R3)(R4))aC(=S)-,ENTRE OTROS; U ES UN ENLACE, -S(O)1-2-, O, ENTRE OTROS; b ES UN ENTERO DE 0 A 2; R1 Y R5 SON H, ALQUILO, ALQUENILO, ENTRE OTROS; R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 Y R18 SON H, ALQUILO, ALQUENILO, ENTRE OTROS; c, d, e, f, g Y h SON UN ENTERO DE 0 A 4; X, Y y Z SON O, N(R5),C(O), ENTRE OTROS; L Y M SON CICLOALQUILENO, HETEROCICLOALQUILENO, ALQUENILENO, ENTRE OTROS; s Y t SON 1 O 2. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE ASPARTIL PROTEASA Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, ENFERMEDADES COGNITIVAS, ENTRE OTRAS
PE2006000654A 2005-06-14 2006-06-12 Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa PE20070078A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69054205P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
PE20070078A1 true PE20070078A1 (es) 2007-03-08

Family

ID=37309231

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000654A PE20070078A1 (es) 2005-06-14 2006-06-12 Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa

Country Status (10)

Country Link
US (2) US7812013B2 (es)
EP (1) EP1902057B1 (es)
JP (1) JP2008543841A (es)
CN (1) CN101193892A (es)
AR (1) AR053902A1 (es)
CA (1) CA2609562A1 (es)
MX (1) MX2007016185A (es)
PE (1) PE20070078A1 (es)
TW (1) TW200716645A (es)
WO (1) WO2006138195A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2008516945A (ja) * 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ化合物およびそれらの使用
CN101084198A (zh) * 2004-10-15 2007-12-05 阿斯利康(瑞典)有限公司 取代的氨基－嘧啶酮及其用途
JP2008523139A (ja) * 2004-12-14 2008-07-03 アストラゼネカ・アクチエボラーグ 置換アミノピリジン類及びその使用
EP1896032B1 (en) * 2005-06-14 2012-10-31 Merck Sharp & Dohme Corp. The preparation and use of compounds as protease inhibitors
AR053902A1 (es) * 2005-06-14 2007-05-23 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos
AR054620A1 (es) * 2005-06-14 2007-07-04 Schering Corp Inhibidores de aspartil proteasas
EP1896478B1 (en) 2005-06-14 2014-05-21 Merck Sharp & Dohme Corp. Aspartyl protease inhibitors
WO2007058581A1 (en) * 2005-11-15 2007-05-24 Astrazeneca Ab Novel 2-aminopyrimidine derivatives and their use
US20080318985A1 (en) * 2005-11-15 2008-12-25 Astrazeneca Ab Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use
TW200804290A (en) * 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
EP1951680A4 (en) * 2005-11-15 2011-08-10 Astrazeneca Ab NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
WO2007058601A1 (en) * 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) * 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
AR058381A1 (es) * 2005-12-19 2008-01-30 Astrazeneca Ab Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
US20090099217A1 (en) * 2006-04-05 2009-04-16 Astex Therapeutics Ltd. 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
AU2007258435A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815447A (en) * 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
US20080051420A1 (en) * 2006-06-14 2008-02-28 Astrazeneca Ab New Compounds 317
TW200815349A (en) * 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
TW200831484A (en) * 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200902503A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
TW200902499A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
EP2200990A1 (en) 2007-09-06 2010-06-30 Schering Corporation Gamma secretase modulators
EP2217604A1 (en) 2007-11-05 2010-08-18 Schering Corporation Gamma secretase modulators
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
CN102282145A (zh) 2008-11-13 2011-12-14 先灵公司 γ分泌酶调节剂
TW201020244A (en) * 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
US20100125081A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574
US20100125087A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
EP2379563B1 (en) 2008-12-22 2014-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
CA2747750A1 (en) 2008-12-22 2010-07-01 Theodros Asberom Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443119A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
WO2010147973A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
PH12013501368A1 (en) 2011-02-08 2013-08-28 Merck Patent Gmbh Aminostatin derivatives for the treatment of arthrosis
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
CA2867891C (en) 2012-03-19 2021-09-14 Buck Institute For Research On Aging App specific bace inhibitors (asbis) and uses thereof
US9624264B2 (en) 2012-07-24 2017-04-18 Merck Patent Gmbh Hydroxystatin derivatives for the treatment of arthrosis
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
ES2769578T3 (es) 2013-02-12 2020-06-26 Buck Inst Res Aging Hidantoínas que modulan el procesamiento de APP mediado por BACE
JP6321685B2 (ja) 2013-02-25 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ２−アミノ−３，４−ジヒドロ−キナゾリン誘導体、およびそのカテプシンｄ阻害剤としての使用
ES2759060T3 (es) 2013-08-06 2020-05-07 Merck Patent Gmbh Administración intraarticular de pepstatina para la artrosis
EP3416647A4 (en) 2016-02-18 2019-10-23 Merck Sharp & Dohme Corp. N3-SUBSTITUTED IMINOPYRIMIDINONE AS ANTIMALARIAMIDAL
US10958463B1 (en) * 2018-03-26 2021-03-23 Lynq Technologies, Inc. Pairing multiple devices into a designated group for a communication session
EP4076659A1 (en) * 2019-12-19 2022-10-26 Latvian Institute Of Organic Synthesis Macrocyclic amides acting as plasmepsin inhbitors for the treatment of malaria

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200123A (en) * 1962-01-26 1965-08-10 Richardson Merreil Inc Imidazoquinolines
US3197476A (en) * 1962-12-06 1965-07-27 Air Prod & Chem Method of synthesis of 1-acyl imidazoles
DE69016430T2 (de) 1989-06-09 1995-06-01 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
FR2719843B1 (fr) 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
FR2741072B1 (fr) 1995-11-09 1997-12-12 Synthelabo Derives d'oxazolidin-2-one, leur preparation et leur application en therapeutique
FR2741073B1 (fr) 1995-11-09 1997-12-12 Synthelabo Derives de 4,5-dihydroimidazo(1,2-a)pyrrolo(1,2,3-cd) benzimidazole, leur preparation et leur application en therapeutique
BR9707086A (pt) * 1996-01-26 1999-04-13 Clarence Webster Andrews, Iii. Inibidores de proteinase aspartila
FR2747678B1 (fr) 1996-04-22 1998-05-22 Synthelabo Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) * 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6294554B1 (en) * 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
JP4012068B2 (ja) * 2000-12-22 2007-11-21 シェーリング コーポレイション ムスカリンアンタゴニスト
AU2002306734A1 (en) 2001-03-15 2002-10-03 The Johns Hopkins University Inhibitors of plasmepsins
US6706885B2 (en) 2001-06-06 2004-03-16 Merck & Co., Inc. Process for preparing integrin antagonist intermediates
CN1301972C (zh) 2001-10-10 2007-02-28 先灵公司 作为毒覃碱拮抗剂的哌啶化合物
GB0315654D0 (en) * 2003-07-03 2003-08-13 Novartis Ag Organic compounds
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2548388A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006022698A1 (en) * 2004-08-10 2006-03-02 Thomson Licensing Method and apparatus for controlling a display function
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
AR053902A1 (es) 2005-06-14 2007-05-23 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos
WO2007092839A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)

Also Published As

Publication number Publication date
JP2008543841A (ja) 2008-12-04
EP1902057A1 (en) 2008-03-26
EP1902057B1 (en) 2013-10-23
CN101193892A (zh) 2008-06-04
TW200716645A (en) 2007-05-01
US20060281729A1 (en) 2006-12-14
US8557798B2 (en) 2013-10-15
MX2007016185A (es) 2008-03-07
AR053902A1 (es) 2007-05-23
WO2006138195A1 (en) 2006-12-28
US20100063121A1 (en) 2010-03-11
CA2609562A1 (en) 2006-12-28
US7812013B2 (en) 2010-10-12

Similar Documents

Publication Publication Date Title
PE20070078A1 (es) Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
UY27918A1 (es) Derivados de benzodioxol
PE20051150A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
AR053748A1 (es) Entidades quimicas, composiciones y metodos.
ECSP066968A (es) Compuestos de metil-aril o heteroaril-amida sustituida
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20070606L (no) Inhibitorer av IAP
SE0202133D0 (sv) Novel compounds
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
SE0403171D0 (sv) New compounds
PE20071161A1 (es) Derivados de urea sustituidos como moduladores del sarcomero cardiaco
TNSN08522A1 (en) Cinnamoyl-piperazine derivatives and their use as par - 1 antagonists
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PA8573501A1 (es) Derivados de benzoxazina y su empleo
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia

Legal Events

Date Code Title Description
FC Refusal